No Data
No Data
[Brokerage Focus] China Post Securities expects the pharmaceutical sector to continue to rise uniformly, suggesting prioritizing the layout of various segmented sectors and leading companies in the first and second tiers during the general rise phase.
Golden Herald Financial News | China Post Securities stated that since the end of September, the pharmaceutical sector has been boosted by the national comprehensive incremental policy, solidly promoting the economy towards a higher-quality structure under the heavy bullish push, leading to a rapid rebound of the index by about 29%, reversing the continuous decline of nearly 4 years. Looking at the current PE (TTM), A-share pharmaceuticals are at 32 times, and Hong Kong stocks at 23 times. The previous continuous decline has already deviated from the fundamentals. The bank believes that the increase in market risk appetite will accelerate the sector's valuation repair. As of H1 2024, the institutions hold a 7.3% stake in the CSI SWS Health Care Index sector, which, although slightly lower than the end of 2023, still remains at a historically high level, indicating a general positive sentiment among institutions.
Trending Industry Today: JOINN Leads Gains In CRO Stocks
Hong Kong stocks are showing abnormal movements | CRO concept stocks continued to rise in the morning, selling businesses may alleviate doubts, the industry's investment and financing vitality is expected to recover rapidly.
Concept stocks of CRO continue to rise in early trading. As of the time of publication, Joinn Laboratories (06127) rose by 16.04% to HKD 13.02; Pharmaron (03759) rose by 12.9% to HKD 22.15; Tigermed (03347) rose by 5.09% to HKD 55.7; Wuxi Apptec (02359) rose by 2.61% to HKD 68.85; Wuxi Bio (02269) rose by 2.1% to HKD 21.9.
Hong Kong stock unusual movement | Pharmaron (03759) increase expands to 20%. Biomedical investment and financing are expected to recover as the company's new signed order amount in the first half of the year exceeds 15%.
Pharmaron (03759) has expanded its gain to 20%, as of the deadline, it has increased by 19.5%, closing at 19 Hong Kong dollars, with a turnover of 0.18 billion Hong Kong dollars.
Biomedical sector showing strong performance, Pharmaron (03759) rose by 14.97%. Institutions believe there is still room for further increase in sector valuation.
Golden Finance News | The biomedical sector is showing strong performance, with Pharmaron (03759) up 14.97%, Remegen (09995) up 13.59%, Tigermed (03347) up 12.58%, Wuxi Bio (02269) up 11.79%, Wuxi Apptec (02359) up 10.56%, Akeso (09926) up 8.92%. In terms of news, Guoyuan International believes that the main reason for the outperformance of the pharmaceutical sector in this round of large gains is due to the deeper decline in the pharmaceutical sector in the previous period (as of September 23, MSCI China Meheco Group Index has fallen 23% year-to-date), sector.
Hong Kong stock market anomaly | CRO concept stocks lead the gains. The US Biological Safety Act is unlikely to be implemented this year, and medical investment and financing are expected to recover rapidly in the rate-cut cycle.
CRO concept stocks performed well in the morning trading session, as of the time of publication, Wuxi AppTec (02359) rose by 7.32% to HKD 64.55; Tigermed (03347) rose by 7.02% to HKD 51.05; Wuxi Bio (02269) rose by 6.72% to HKD 20; Pharmaron (03759) rose by 6.67% to HKD 16.96.